Abiopharma

🔍 Levin Jonathan Reisin (Director)

Company: GCM Grosvenor Inc. (GCMG)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 91,305 shares of Class A Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 732,306.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 42,813 shares of Class A Common Stock at $13.86 per share (Direct)
  Date: 2026-08-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 689,493.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 91,305 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F1, F1

Footnotes:

• F1: Represents restricted stock units ("RSUs") that were granted under the Issuer's Amended and Restated 2020 Incentive Award Plan on March 1, 2026, and vested in full on August 15, 2026. Shares of Class A common stock of the Issuer were delivered to the Reporting Person in settlement of vested RSUs on August 15, 2026.
• F2: Each RSU represents the contingent right to receive one share of Class A common stock of the Issuer.
• F3: Represents shares of Class A common stock that have been withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of RSUs that vested on August 15, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested RSUs and do not constitute any open-market sale.